Lanreotide vs LL-37
Overview
Lanreotide is primarily a hormonal peptide, while LL-37 is used for immune support.
This page compares Lanreotide and LL-37 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Lanreotide | LL-37 | |
|---|---|---|
| Category | Hormonal | Immune Support |
| Regulatory status (US) | FDA approved | Compounding (Rx) — Apr 2026 |
| Typical dosage | 60-120 mg | 2-5 mg |
| Frequency | every 4 weeks | twice weekly |
| Reported benefits | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones | Antimicrobial activity, immune modulation, wound healing, anti-inflammatory |
| Reported side effects | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases | Generally safe, minimal side effects |
Key differences
Primary use. Lanreotide is categorised under Hormonal, while LL-37 falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Lanreotide: FDA-approved. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Lanreotide is typically dosed at 60-120 mg (every 4 weeks). LL-37 is typically dosed at 2-5 mg (twice weekly).
Can you stack them?
Some protocols combine peptides, but stacking Lanreotide and LL-37 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Lanreotide and LL-37?
- Lanreotide is primarily a hormonal peptide, while LL-37 is used for immune support. Lanreotide is FDA-approved for one or more indications, whereas LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- What is LL-37 used for?
- Antimicrobial defense peptide.
- Can you take Lanreotide and LL-37 together?
- Some users combine peptides within a single protocol, but stacking Lanreotide and LL-37 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Lanreotide or LL-37 FDA-approved?
- Lanreotide is FDA-approved for one or more indications. LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Lanreotide — full monograph: mechanism, research, dosing & references
- LL-37 — full monograph: mechanism, research, dosing & references